Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

NCT ID: NCT01838694

Last Updated: 2017-01-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2015-08-31

Brief Summary

The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4 weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.

Conditions

Lupus Erythematosus, Systemic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Ala-Cpn10

Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.

Group Type: EXPERIMENTAL

Ala-Cpn10

Intervention Type: BIOLOGICAL

Interventions

Ala-Cpn10

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

To be entered on study, subjects must meet the following criteria:

1. Male or female

2. Age 18 - 75 years

3. Patients fulfilling at least 4 criteria for SLE as defined by the American College of Rheumatology (ACR)

4. Laboratory values as follows:

Documented ANA titer ≥ 1:160 or positive anti-dsDNA antibodies at, or any time prior to screening (verifiable laboratory result)

5. Not pregnant or breast-feeding

6. If corticosteroids are required for disease stability prior to study entry, able to tolerate a stable dose of ≤ 0.3 mg/kg/day of prednisone or equivalent for the duration of the study.

7. Agreement to use an effective form of contraception for the duration of the study.

8. Ability to understand and give consent.

9. Willing to participate and able to comply with the study requirements, procedures and visits.

Mild SLE only

10. Present with mild active SLE disease

Moderate SLE only

11. Present with active SLE disease based on SLE disease activity score (SLEDAI) ≥4 and ≤10

12. MCP-1 urinary level > 35 pg/ml

13. IL-6 serum level > 10 pg/ml

14. Meets the American College of Rheumatology (ACR) conditions for "renal disorder" as one of the diagnostic criteria for SLE i.e.

1. Persistent proteinuria between 0.5 and 1.0 grams per day or > than 3+ by dipstick OR

2. Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed

OR

15. Physician (Pathologist) diagnosis of lupus nephritis of no greater severity than:

1. Class I - Minimal mesangial lupus nephritis, OR

2. Class II - Mesangial proliferative lupus nephritis, in accordance with the International Society of Nephrology (ISN) and the Renal Pathology Society (RPS) 2003 histological classification.

With diagnosis made ≥ 6 months prior to study commencement.

Exclusion Criteria

1. Active severe SLE flare with central nervous system (CNS) and/or renal manifestations, pericarditis, active pleuritis, active peritonitis or other SLE manifestations requiring treatment not allowed by the study protocol within 4 weeks of screening

2. Pregnant or breast-feeding

3. Lack of peripheral venous access.

4. History of cardiovascular disease. An acute cardiovascular event within 12 months of study entry, including arterial or venous thrombosis (blood clots).

5. Requirement for a stable dose of corticosteroid >0.3 mg/kg/day of prednisone or equivalent.

6. Active therapy with human or murine monoclonal antibodies (i.e. belimumab), within 2 months of study entry.

7. Any experimental therapy within 3 months of study entry.

8. Therapy with cyclophosphamide p.o or parenteral; pulse methylprednisolone or IVIG within 4-6 weeks.

9. Subjects being treated with sulfonylureas.

10. Subjects with any the following laboratory abnormalities: serum creatinine >3.0 mg/dL, WBC <3,500/μL, ANC <3,000/μL, absolute lymphocyte count ≤500/μL, Hgb <8.0 g/dL, platelets <50,000/μL, ALT and/or AST >1.5 x upper limit of normal (ULN), alkaline phosphatase >1.5 ULN.

11. Personal or psychiatric condition that precludes the subject being able to comply with the study requirements or understand and agree to the informed consent process.

12. Recent systemic bacterial, fungal, viral, or parasitic infections. Have required management/treatment or hospitalization for any infection within the last 4 weeks before screening.

13. History of malignancy - except completely excised basal cell carcinoma.

14. Impaired hepatic function

15. Body weight of 260lbs/120kg or more (BMI > 35)

16. History of tuberculosis (TB) or active, continuing treatment for TB

17. History of or current alcohol or substance abuse

Mild SLE only

18. Active lupus nephritis and/or severe renal impairment (estimated or measured GFR < 50% predicted for age and gender)

Moderate SLE only

19. Subjects with recently diagnosed lupus nephritis (diagnosis made <6 months prior to commencement of study

20. Subjects with active urinary sediment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Invion, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Abel Buchheim Pharmaceutical Research

Miami, Florida, United States

Northwestern University School of Medicine

Chicago, Illinois, United States

Altoona Arthritis and Osteoporosis Center

Altoona, Pennsylvania, United States

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Metroplex Clinical Research Center

Dallas, Texas, United States

Countries

United States

Other Identifiers

IVXCpn001

Identifier Type: -

Identifier Source: org_study_id